Arden Trust’s Edwards Lifesciences EW Stock Holding History

Arden Trust’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,048	Closed	-$300	–	377
2016 Q2	$300	Buy	+9,048	New	+$310K	0.02%	471

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Arden Trust's EW Position: Q3 2016 in Review

Arden Trust sold out of Edwards Lifesciences (EW) in Q3 2016, closing a stake of 9,048 shares — an estimated $300 sold.

Arden Trust first reported a position in EW in Q2 2016 and held it in 1 quarter. The position peaked at $300 in Q2 2016. 693 funds tracked by Wall St. Rank hold EW as of Q3 2016.

Arden Trust reported no remaining Edwards Lifesciences position as of Q3 2016 after selling out during the quarter.
Arden Trust sold 9,048 Edwards Lifesciences shares in Q3 2016, an estimated $300.
Arden Trust first reported a position in Edwards Lifesciences in Q2 2016 and held it in 1 quarter.
Arden Trust's Edwards Lifesciences position peaked at $300 in Q2 2016.
693 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2016.

Based on Arden Trust's 13F filing for Q3 2016, filed 14 Oct 2016.